UBS Group’s Virtus Biotech ETF BBP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1
| Closed | -$83 | – | 10448 |
|
|
2026
Q1 | $83 | Buy |
+1
| New | +$82 | ﹤0.01% | 10144 |
|
|
2025
Q2 | – | Sell |
-488
| Closed | -$28.6K | – | 10250 |
|
|
2025
Q1 | $28.6K | Buy |
488
+241
| +98% | +$14.8K | ﹤0.01% | 7978 |
|
|
2024
Q4 | $14.8K | Buy |
+247
| New | +$15.6K | ﹤0.01% | 8068 |
|
|
2024
Q1 | – | Sell |
-448
| Closed | -$26K | – | 9307 |
|
|
2023
Q4 | $26K | Buy |
+448
| New | +$22.7K | ﹤0.01% | 6936 |
|
|
2023
Q2 | – | Sell |
-175
| Closed | -$8.62K | – | 8918 |
|
|
2023
Q1 | $8.62K | Sell |
175
-894
| -84% | -$44.9K | ﹤0.01% | 7709 |
|
|
2022
Q4 | $52.7K | Buy |
1,069
+139
| +15% | +$6.65K | ﹤0.01% | 6730 |
|
|
2022
Q3 | $42K | Sell |
930
-614
| -40% | -$28.3K | ﹤0.01% | 6512 |
|
|
2022
Q2 | $64K | Buy |
1,544
+1,029
| +200% | +$40.9K | ﹤0.01% | 5735 |
|
|
2022
Q1 | $22K | Buy |
515
+54
| +12% | +$2.32K | ﹤0.01% | 7332 |
|
|
2021
Q4 | $23K | Buy |
461
+431
| +1,437% | +$21.4K | ﹤0.01% | 7670 |
|
|
2021
Q3 | $2K | Sell |
30
-67
| -69% | -$3.46K | ﹤0.01% | 8927 |
|
|
2021
Q2 | $5K | Sell |
97
-1,073
| -92% | -$56.6K | ﹤0.01% | 8530 |
|
|
2021
Q1 | $61K | Sell |
1,170
-1,222
| -51% | -$68.2K | ﹤0.01% | 6351 |
|
|
2020
Q4 | $127K | Buy |
2,392
+882
| +58% | +$45.2K | ﹤0.01% | 5532 |
|
|
2020
Q3 | $72K | Sell |
1,510
-615
| -29% | -$28.6K | ﹤0.01% | 5392 |
|
|
2020
Q2 | $101K | Buy |
2,125
+446
| +27% | +$19.9K | ﹤0.01% | 5295 |
|
|
2020
Q1 | $63K | Buy |
1,679
+233
| +16% | +$9.63K | ﹤0.01% | 5634 |
|
|
2019
Q4 | $63K | Sell |
1,446
-1,764
| -55% | -$70.8K | ﹤0.01% | 6228 |
|
|
2019
Q3 | $115K | Buy |
3,210
+1,112
| +53% | +$42.6K | ﹤0.01% | 5688 |
|
|
2019
Q2 | $86K | Buy |
2,098
+2,024
| +2,735% | +$83.3K | ﹤0.01% | 5482 |
|
|
2019
Q1 | $3K | Sell |
74
-1,163
| -94% | -$48.7K | ﹤0.01% | 7322 |
|
|
2018
Q4 | $43K | Sell |
1,237
-617
| -33% | -$23.5K | ﹤0.01% | 6223 |
|
|
2018
Q3 | $84K | Buy |
1,854
+769
| +71% | +$34.4K | ﹤0.01% | 5730 |
|
|
2018
Q2 | $48K | Buy |
1,085
+55
| +5% | +$2.33K | ﹤0.01% | 5984 |
|
|
2018
Q1 | $43K | Sell |
1,030
-547
| -35% | -$23K | ﹤0.01% | 5826 |
|
|
2017
Q4 | $64K | Buy |
1,577
+1,542
| +4,406% | +$61.6K | ﹤0.01% | 5657 |
|
|
2017
Q3 | $1K | Sell |
35
-57
| -62% | -$2.28K | ﹤0.01% | 7557 |
|
|
2017
Q2 | $4K | Sell |
92
-2,290
| -96% | -$85.5K | ﹤0.01% | 7196 |
|
|
2017
Q1 | $90K | Sell |
2,382
-1,505
| -39% | -$55.1K | ﹤0.01% | 5130 |
|
|
2016
Q4 | $127K | Buy |
+3,887
| New | +$127K | ﹤0.01% | 5125 |
|
|
2016
Q3 | – | Sell |
-1,538
| Closed | -$41K | – | 7668 |
|
|
2016
Q2 | $41K | Buy |
+1,538
| New | +$40.6K | ﹤0.01% | 5664 |
|
|
2016
Q1 | – | Sell |
-1,213
| Closed | -$37K | – | 7634 |
|
|
2015
Q4 | $37K | Sell |
1,213
-218
| -15% | -$6.61K | ﹤0.01% | 6108 |
|
|
2015
Q3 | $40K | Buy |
1,431
+273
| +24% | +$9.21K | ﹤0.01% | 6019 |
|
|
2015
Q2 | $41K | Sell |
1,158
-21
| -2% | -$690 | ﹤0.01% | 6168 |
|
|
2015
Q1 | $37K | Buy |
+1,179
| New | +$34.5K | ﹤0.01% | 6319 |
|
Other funds holding BBP
CAMG
WI
UBS Group's BBP Position: Q2 2026 in Review
UBS Group sold out of Virtus Biotech ETF (BBP) in Q2 2026, closing a stake of 1 share — an estimated $83 sold.
UBS Group first reported a position in BBP in Q1 2015 and held it in 35 quarters. The position peaked at $127K in Q4 2020. 25 funds tracked by Wall St. Rank hold BBP as of Q2 2026.
- UBS Group reported no remaining Virtus Biotech ETF position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 1 Virtus Biotech ETF share in Q2 2026, an estimated $83.
- UBS Group first reported a position in Virtus Biotech ETF in Q1 2015 and held it in 35 quarters.
- UBS Group's Virtus Biotech ETF position peaked at $127K in Q4 2020.
- 25 funds tracked by Wall St. Rank held Virtus Biotech ETF as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.